1. Home
  2. GAIN vs ABVX Comparison

GAIN vs ABVX Comparison

Compare GAIN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAIN
  • ABVX
  • Stock Information
  • Founded
  • GAIN 2005
  • ABVX 2013
  • Country
  • GAIN United States
  • ABVX France
  • Employees
  • GAIN N/A
  • ABVX N/A
  • Industry
  • GAIN Finance: Consumer Services
  • ABVX
  • Sector
  • GAIN Finance
  • ABVX
  • Exchange
  • GAIN Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • GAIN 521.2M
  • ABVX 511.3M
  • IPO Year
  • GAIN 2005
  • ABVX N/A
  • Fundamental
  • Price
  • GAIN $14.05
  • ABVX $7.90
  • Analyst Decision
  • GAIN Hold
  • ABVX Buy
  • Analyst Count
  • GAIN 2
  • ABVX 4
  • Target Price
  • GAIN $13.50
  • ABVX $31.50
  • AVG Volume (30 Days)
  • GAIN 160.6K
  • ABVX 254.8K
  • Earning Date
  • GAIN 08-04-2025
  • ABVX 08-11-2025
  • Dividend Yield
  • GAIN 15.36%
  • ABVX N/A
  • EPS Growth
  • GAIN N/A
  • ABVX N/A
  • EPS
  • GAIN 1.78
  • ABVX N/A
  • Revenue
  • GAIN $93,662,000.00
  • ABVX $11,444,012.00
  • Revenue This Year
  • GAIN $6.09
  • ABVX $284.20
  • Revenue Next Year
  • GAIN $3.93
  • ABVX N/A
  • P/E Ratio
  • GAIN $8.05
  • ABVX N/A
  • Revenue Growth
  • GAIN 7.28
  • ABVX 128.98
  • 52 Week Low
  • GAIN $11.42
  • ABVX $4.77
  • 52 Week High
  • GAIN $15.34
  • ABVX $14.16
  • Technical
  • Relative Strength Index (RSI)
  • GAIN 54.21
  • ABVX 65.79
  • Support Level
  • GAIN $13.85
  • ABVX $7.41
  • Resistance Level
  • GAIN $14.39
  • ABVX $8.13
  • Average True Range (ATR)
  • GAIN 0.23
  • ABVX 0.45
  • MACD
  • GAIN 0.02
  • ABVX 0.12
  • Stochastic Oscillator
  • GAIN 72.31
  • ABVX 93.03

About GAIN Gladstone Investment Corporation Business Development Company

Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: